Gentamicin in older adults
Indication: Gram-negative bacterial infections in older adults
Interactive gentamicin population PK simulator for older adults showing the independent impact of frailty, creatinine clearance, and lean body weight on exposure.
Drug Overview
Clinical Context
- Molecular Target
- 30S ribosomal subunit
- Drug Class
- Aminoglycoside antibiotic
- Therapeutic Area
- Infectious diseases / Geriatrics
- Indication
- Gram-negative bacterial infections in older adults
- Route of Administration
- Intravenous
Model Information
- Model Type
- One-compartment population PK
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
Pharmacokinetic Parameters
Additional Parameters
| Parameter | Value |
|---|---|
| V L | 14.6 |
| CL m L min | 102 |
| V equation | 14.6*(LBW/53) |
| CL equation | 102*(CrCL/45.2)*0.876^FRAIL |
| BSV V CV pct | 10.4 |
| BSV CL CV pct | 20.5 |
| frailty definition | REFS >= 8 |
Parameters sourced from published population pharmacokinetic models. Values represent typical population estimates; individual patient parameters may vary.
About This Simulator
This interactive pharmacokinetic simulator for Gentamicin in older adults allows you to explore concentration-time profiles under different dosing scenarios. The underlying One-compartment population PK model characterizes the pharmacokinetics of this aminoglycoside antibiotic following intravenous administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Gentamicin in older adults PK simulator?
This is a free, interactive pharmacokinetic simulator for Gentamicin in older adults used in Gram-negative bacterial infections in older adults. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Gentamicin in older adults belong to?
Gentamicin in older adults is classified as a Aminoglycoside antibiotic that targets 30S ribosomal subunit. It is used in the Infectious diseases / Geriatrics therapeutic area.
What route of administration does this model simulate?
This simulator models Intravenous administration of Gentamicin in older adults. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a One-compartment population PK model. This model characterizes the time-course of drug concentrations following dosing.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Ready to Simulate?
Launch the Gentamicin in older adults simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community